Moderna Files for U.S. Authorization of COVID-19 Shot for Kids Under 6

Read Time:1 Minute, 11 Seconds

April 28. Moderna Inc (MRNA.O) said on Thursday it asked U.S. regulators to authorize its COVID-19 vaccine for children under the age of 6, which would make it the first shot against the coronavirus available for those under 5-years-old.

The COVID-19 vaccine from Pfizer Inc (PFE.N) and BioNTech SE (22UAy.DE) is authorized for children 5 and older. But their trial results for 2- to 4-year-olds showed a weaker immune response than in adults, forcing the study to be extended to test a third dose. Pfizer has said that data would come in April.

Moderna released trial data in March showing that its vaccine was safe and generated a similar immune response in young children as for adults, which was the goal of the study.

The Omicron variant of the coronavirus, which has been shown to evade vaccine immunity compared with earlier versions, was predominant during the pediatric trial. The drugmaker said two doses were around 37% effective in preventing infections in 2- to 5-year-olds and 51% effective for children ages 6 months to 2 years.

It is not clear how many U.S. parents of will want to vaccinate their children in the age group. Only 28% of U.S. children in the 5 to 11 age group are fully vaccinated, and COVID-19 is often more mild in children than adults.

Source: Reuters

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
117220cookie-checkModerna Files for U.S. Authorization of COVID-19 Shot for Kids Under 6